BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1353229)

  • 1. Oestrogen and progesterone receptor status in breast cancer and development of endometrial abnormalities.
    Cohen I; Altaras M; Rosen DJ; Shapira Y; Cordoba M; Yigael D; Beyth Y
    Lancet; 1992 Aug; 340(8814):312. PubMed ID: 1353229
    [No Abstract]   [Full Text] [Related]  

  • 2. Does tamoxifen change oestrogen and progesterone receptor expression in the endometrium and breast?
    Karck U; Kommoss F
    Eur J Cancer; 2000 Sep; 36 Suppl 4():S45-6. PubMed ID: 11056315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Estrogen and progesterone receptor expression in postmenopausal tamoxifen-exposed endometrial pathologies.
    Cohen I; Beyth Y; Altaras MM; Shapira J; Tepper R; Cardoba M; Yigael D; Figer A; Fishman A; Berenhein J
    Gynecol Oncol; 1997 Oct; 67(1):8-15. PubMed ID: 9345349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormonal manipulation and gynaecological cancer: the tamoxifen dilemma.
    Ross D; Whitehead M
    Curr Opin Obstet Gynecol; 1995 Feb; 7(1):63-8. PubMed ID: 7742519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The endometrial effects of SERMs.
    Cano A; Hermenegildo C
    Hum Reprod Update; 2000; 6(3):244-54. PubMed ID: 10874569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effects of tamoxifen on the female genital tract.
    Senkus-Konefka E; Konefka T; Jassem J
    Cancer Treat Rev; 2004 May; 30(3):291-301. PubMed ID: 15059652
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Tamoxifen-induced progesterone receptors in breast tumors].
    Tsyrlina EV; Semiglazov VF; Nurgaziev KSh; Ivanova OA
    Vopr Onkol; 1991; 37(9-10):916-21. PubMed ID: 1842650
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of tamoxifen on steroid hormone receptors and hormone concentration and the results of DNA analysis by flow cytometry in endometrial carcinoma.
    Nola M; Jukić S; Ilić-Forko J; Babić D; Uzarević B; Petrovecki M; Suchanek E; Skrablin S; Dotlić S; Marusić M
    Gynecol Oncol; 1999 Mar; 72(3):331-6. PubMed ID: 10053103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tamoxifen and endometrial lesions.
    Neven P
    Lancet; 1993 Aug; 342(8869):452. PubMed ID: 8102426
    [No Abstract]   [Full Text] [Related]  

  • 10. Estrogen and progesterone receptor expression of decidual endometrium in a postmenopausal woman treated with tamoxifen and megestrol acetate.
    Cohen I; Shulman A; Altaras M; Tepper R; Cordoba M; Beyth Y
    Gynecol Obstet Invest; 1994; 38(2):127-9. PubMed ID: 7959340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The nature of tamoxifen action in the control of female breast cancer.
    Kodama M; Kodama T
    In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of GPR30 in endometrial pathology after tamoxifen for breast cancer.
    Ignatov T; Eggemann H; Semczuk A; Smith B; Bischoff J; Roessner A; Costa SD; Kalinski T; Ignatov A
    Am J Obstet Gynecol; 2010 Dec; 203(6):595.e9-16. PubMed ID: 20965484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endometrial cancer and tamoxifen.
    Burke C
    Clin J Oncol Nurs; 2005 Apr; 9(2):247-9. PubMed ID: 15853168
    [No Abstract]   [Full Text] [Related]  

  • 14. Immuno-biochemical assay for determination of nuclear steroid receptors during tamoxifen therapy.
    Vering A; Vockel A; Stegmüller M; Bender HG
    J Cancer Res Clin Oncol; 1993; 119(7):415-20. PubMed ID: 8491762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen mediated human endometrial carcinogenesis may not involve estrogenic pathways: a preliminary note.
    Kuwashima Y; Kurosumi M; Kobayashi Y; Tanuma J; Suemasu K; Higashi Y; Kasamatsu T; Shiromizu K; Matsuzawa M; Kishi K
    Anticancer Res; 1996; 16(5A):2993-6. PubMed ID: 8917418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endometrial carcinoma and tamoxifen: clearing up a controversy.
    Andersson M; Storm HH; Mouridsen HT
    Clin Cancer Res; 1996 Jan; 2(1):223-4. PubMed ID: 9816110
    [No Abstract]   [Full Text] [Related]  

  • 17. Variation of estrogen and progesterone receptor status in breast cancer after tamoxifen therapy.
    Melchor JC; Rodríguez-Escudero FJ; Luján S; Corcóstegui B
    Oncology; 1990; 47(6):467-70. PubMed ID: 2123023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tamoxifen, screening and new oestrogen receptor modulators.
    Neven P; Vergote I
    Best Pract Res Clin Obstet Gynaecol; 2001 Jun; 15(3):365-80. PubMed ID: 11476559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endometrial cancer during tamoxifen treatment.
    Sasieni P
    Lancet; 1994 Apr; 343(8903):978. PubMed ID: 7909033
    [No Abstract]   [Full Text] [Related]  

  • 20. Endometrial carcinoma can develop in patients on tamoxifen therapy.
    Omar SZ; Sivanesaratnam V
    Med J Malaysia; 1999 Jun; 54(2):280-2. PubMed ID: 10972045
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.